Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04666038

Recruitment Status : Active, not recruiting

First Posted : December 14, 2020

Last Update Posted : April 26, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Eli Lilly and Company

Information provided by (Responsible Party):

Eli Lilly and Company ( Loxo Oncology, Inc. )

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	November 1, 2023
Estimated Study Completion Date :	May 2027

To Top